Krsnaa Diagnostics Q4 FY26 PAT jumps 102% YoY

Key takeaway from the March-quarter print

Krsnaa Diagnostics reported a sharp rise in profit for the quarter ended March 31, 2026, even as revenue growth stayed in low single digits. Consolidated net profit for Q4 FY26 rose 101.74% year-on-year to ₹41.72 crore, compared with ₹20.68 crore in Q4 FY25. Revenue from operations increased 3.5% YoY to ₹192.60 crore versus ₹186.08 crore in the year-ago quarter. The company also reported profit before tax (PBT) of ₹51.70 crore for Q4 FY26, up 80.71% from ₹28.61 crore in Q4 FY25.

Q4 FY26 numbers: profit up, revenue steady

The quarter’s earnings profile points to margin-led improvement rather than a demand-led jump in topline. Along with the reported PAT, the company disclosed an EBITDA figure of ₹54.90 crore for Q4 FY26, compared with ₹53.00 crore in Q4 FY25. EBITDA margin was reported at 29% in both periods, indicating stable operating profitability on a year-on-year basis.

In the same set of disclosures, Krsnaa Diagnostics also presented the quarter’s revenue in rupee million terms, consistent with the crore figures. Revenue from operations for Q4 FY26 was ₹192.604 crore (₹1,926.04 million), compared with ₹186.076 crore (₹1,860.76 million) in the corresponding quarter last year. PAT for Q4 FY26 was ₹41.718 crore (₹417.18 million) versus ₹20.678 crore (₹206.78 million) in Q4 FY25.

FY26 performance: PAT rises 31% on 7.75% sales growth

For the full year ended March 31, 2026, Krsnaa Diagnostics reported consolidated net profit of ₹101.43 crore, up 30.69% from ₹77.61 crore in FY25. Revenue from operations for FY26 rose 7.75% to ₹772.77 crore, compared with ₹717.16 crore in FY25.

The company also reported the same annual numbers in rupee million terms, which translate back to the above crore values. FY26 PAT was ₹101.431 crore (₹1,014.31 million) versus ₹77.608 crore (₹776.08 million) in FY25. FY26 revenue from operations stood at ₹772.774 crore (₹7,727.74 million) compared with ₹717.160 crore (₹7,171.60 million) in FY25.

How the result compared with cited street expectations

The article text also cites analyst consensus estimates projecting Krsnaa Diagnostics’ Q4 FY26 revenue at about ₹308 crore and PAT at about ₹34 crore, with an expected EBITDA margin of around 11%. The reported results in the same text show Q4 revenue from operations at ₹192.60 crore and PAT at ₹41.72 crore, and an EBITDA margin of 29%.

Since these figures sit side-by-side in the provided material, the key point for readers is that the cited estimate set and the reported financials do not align on revenue and margin levels. The article does not provide a reconciliation or an explanation for the difference in the estimate base versus the reported revenue from operations.

Stock reaction: marginal decline in early reads

On the market side, the text contains two price references. One datapoint said shares of Krsnaa Diagnostics shed 0.27% to ₹553.65 on the BSE. Another datapoint in the same input noted the stock moved down 1.72% from a previous close of ₹821.35 and last traded at ₹807.25.

These two price points appear to be from different snapshots, and the input does not specify whether they correspond to different exchanges, different timestamps, or a separate period. What is clear is that the immediate reaction captured in the text was negative in both cases, but the magnitude and price level differ.

Conference call: management to discuss results on May 26

Krsnaa Diagnostics scheduled a post-earnings conference call for May 26, 2026 at 12:30 PM IST to discuss the financial results for the quarter and year ended March 31, 2026. The dial-in details shared include domestic Universal Access Numbers +91 22 6280 1224 and +91 22 7115 8125. International toll-free numbers were listed for the USA (18667462133), UK (08081011573), Singapore (8001012045), and Hong Kong (800964448).

For investors, this call is the next formal checkpoint to hear management commentary on quarterly profitability, the pace of revenue growth, and any operational factors behind the year-on-year changes.

Business context mentioned in the material

The input describes Krsnaa Diagnostics as one of India’s larger differentiated diagnostic service providers with a pan-India presence across radiology and pathology. It highlights partnerships with government hospitals and operations of a substantial number of CT and MRI centers.

The material also includes prior-period operating commentary indicating large-scale throughput. For FY25, it states the company served over 19 million patients and conducted over 61 million tests. It also notes that retail contributed close to 3.5% of overall revenue in one quarter mentioned in the commentary, with an internal aspiration cited of reaching about 5% to 8% in the next year.

Prior-year financial and balance sheet datapoints referenced

Several FY25 datapoints are included in the text that add context to the FY26 comparison. FY25 revenue from operations is stated at ₹717.16 crore and FY25 net profit at ₹77.61 crore, consistent with the FY26 year-on-year calculations presented. The input also references a board-recommended dividend of ₹2.75 per share for FY25.

On the balance sheet, as of March 31, 2025, the company reported gross debt of ₹165.50 crore (₹1,655 million) and cash and cash equivalents of ₹176.00 crore (₹1,760 million). Receivable days were stated at 128 days, attributed in the commentary to transactional delays in Himachal Pradesh and Karnataka.

Snapshot table: Q4 and FY comparison

Full-year table: FY26 vs FY25

Why this result matters for investors

The FY26 and Q4 FY26 numbers show a widening gap between profit growth and revenue growth in the period described. In Q4, revenue grew 3.5% while PAT more than doubled, and PBT rose over 80%. For the full year, revenue rose 7.75% while PAT increased about 31%.

This divergence makes the next layer of detail important, particularly the drivers behind profitability: cost structure, mix, operating leverage, and working capital movement. The input confirms stable EBITDA margin at 29% year-on-year for the quarter and provides working capital context through receivable days data for FY25, but it does not provide FY26 receivables or cash flow details.

Conclusion

Krsnaa Diagnostics ended Q4 FY26 with a 101.74% YoY rise in PAT to ₹41.72 crore, while revenue from operations increased 3.5% to ₹192.60 crore. For FY26, PAT rose 30.69% to ₹101.43 crore on revenue of ₹772.77 crore. The company’s next scheduled step is the post-earnings conference call on May 26, 2026, where management is expected to discuss the quarter and full-year performance.